Rajat Thawani, Assistant Professor at the Knight Cancer Institute at OHSU, shared on LinkedIn: “Zongertinib has already given us a first-line targeted option for HER2-mutant NSCLC with TKD mutations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results